SCHEMBL6458164

SCHEMBL6458164

NC(=O)c1occc1-c1cccc([N+](=O)[O-])c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.51
ALDH1A1 P00352 4/20 0.45
MAPT P10636 4/20 0.45
GAA P10253 2/20 0.45
KDM4E B2RXH2 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MGAM O43451 1/20 0.44
SI P14410 1/20 0.44
PKM P14618 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
NQO2 P16083 1/20 0.44
CDC7 O00311 1/20 0.44
AKR1C3 P42330 2/20 0.43
AKR1C2 P52895 2/20 0.43
LMNA P02545 1/20 0.43
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6683807 0.77 LMNA (0.46) TSHRALDH1A1MAPTLMNANPC1
SCHEMBL6634881 0.77 NUDT1 (0.47) NPC1RAB9A
SCHEMBL6635842 0.77 PARP1 (0.46) CDC7NPC1RAB9ASMN1; SMN2
SCHEMBL6632560 0.77 PARP1 (0.46) KDM4ENQO2CDC7SMN1; SMN2MAPK1
SCHEMBL7256623 0.75 BCAT2 (0.57) TSHRALDH1A1MAPTCDC7AKR1C3
SCHEMBL3033548 0.75 BCAT2 (0.50) TSHRALDH1A1MAPTGAAKDM4E
SCHEMBL6632075 0.73 PARP1 (0.50) ALDH1A1MAPTCDC7LMNANPC1
SCHEMBL29949615 0.73 SLC9A1 (0.48) ALDH1A1KDM4EAKR1C3AKR1C2CES2
SCHEMBL29950025 0.73 RXRA (0.46) ALDH1A1MAPTKDM4ESMN1; SMN2TP53
SCHEMBL28245589 0.73 TSHR (0.81) TSHRALDH1A1MAPTLMNACES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 TSHR 156/4885ALDH1A1 2036/4885MAPT 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.